The MHRA’s newly published 2025-2026 equality duty report documents systematic integration of equity considerations across pharmaceutical regulation affecting medicine access throughout the UK. The report identifies three core implementation areas: regulatory processes, public engagement, and workforce metrics.
Equality impact assessments are now embedded within standard procedures for medicine licensing and ongoing safety monitoring, requiring evaluators to examine how regulatory decisions may disproportionately affect populations characterized by age, disability, race, or socioeconomic status. Public consultation frameworks have been restructured to ensure meaningful participation from communities historically absent from regulatory decision-making processes.
These measurable reforms represent substantive progress in translating health equity principles into operational regulatory practice. By systematizing equity evaluation across distinct functional areas, the MHRA demonstrates a replicable model for how regulatory agencies can advance health justice without compromising pharmaceutical safety standards.
Read the full article on GMJ Newsroom.
Was this article helpful?
GMJ Brief · Key Finding
📰 Read the full article: MHRA Reports Progress on Health Equity Through Regulatory Reform →
